Why Choose Transgenomic?

for your Next Biomarker Identification Program

We use proprietary and groundbreaking MX-ICP (Mulitplexed ICE COLD-PCR) technology

to enrich samples upstream for better accuracy and sensitivity for mutation detection

…and add that to our scientific, clinical and project management expertise

Learn more about MX-ICP
Contact Us About Your Program Goals

The Science to Create Non-Invasive “Liquid Biopsies”

The ability to detect mutations from cell free DNA (cfDNA) in “liquid biopsies” enables more efficient and more effective clinical diagnosis and patient monitoring. Sampling is non-invasive, requiring only a blood draw, allowing simpler and more frequent sample collection. Transgenomic will help you design a “liquid biopsy” to detect the mutations in DNA isolated from bodily fluids that are most appropriate for your product using our personalized biomarker development program.

Who Can Benefit from Our Services and Technology?


Transgenomic will help you detect known and unknown genetic mutations in DNA isolated from blood, serum and other bodily fluids to advance your biomarker development program


If you need to enrich any type of sample for mutant DNA, then take advantage of our proprietary ICE COLD-PCR technology

Clinical Diagnostics

Detecting small amounts of mutant DNA in a liquid or tissue sample can be impossible unless you let our ICE COLD-PCR technology enable you to detect known and unknown mutations with unheard of sensitivity


Transgenomic has made the possibility of true “Liquid Biopsies” a reality for the oncology community with our groundbreaking ICE COLD-PCR

Scientific Expertise Across the Spectrum

Transgenomic provides personalized service for personalized medicine throughout the entire process
—from basic research to an FDA approved companion diagnostic.
We tailor your project to provide you the services you need at each stage of the process.

State-of-art Compliance & Internal Processes

Project Management Expertise

Our extensive project management expertise and systems ensures the best path is taken for development of CE-IVD, PMA and 510k diagnostic products. Our proactive nature ensures timely completion of assay validation studies in accordance with appropriate regulatory standards.

Extensive Design Controls and Standards

We implement design controls and standards which means all assay and platform development is performed under QSR, 21CFR part 11, ISO regulatory standards, CDRH and/or other guidelines, as appropriate for your project. A validated test enables fast entry into clinical trials by ensuring concurrent submission of companion diagnostic test or kit and a drug for regulatory approval.

Fully Integrated Quality Systems

We have established integrated quality systems in a CLIA/CAP facility in support of trial-associated services and future, approved LDT-PMA testing service offerings. We are GMP compliant.

Clinical, Pharmaceutical and Technical Expertise

Our clinical, pharmaceutical and technical expertise has distinguished Transgenomic as a customer-oriented service and development company. Traditionally, we form long-term partnerships to ensure successful entry into the LDT-PMA space.

Capabilities and Technologies

Transgenomic is uniquely qualified to meet your project needs
with the exclusive tools and experience necessary for rapid success

Gene sequencing

Sanger sequencing

Unbiased mutation scanning and detection

Sanger sequencing + SURVEYOR® nuclease

Mutation enrichment

Sanger sequencing + BLOCker sequencing
Sanger sequencing + BLOCker sequencing

Copy number variations, SNPs

High density SNP array

Custom targeted sequencing panels

Next Generation Sequencing (NGS) Ion Torrent

Micro RNA analysis

Next Generation Sequencing (NGS) Ion Torrent


Next Generation Sequencing (NGS) Ion Torrent

Custom gene panels with mutation pre-enrichment using ICP

NGS Ion Torrent + (ICP)

Expression and methylation analysis

TaqMan and Microfluidic capillary electrophoresis, bisulfite treatment

SNP genotyping


DNA and RNA from FFPE, tissues, blood, plasma, serum, CTCs and other bodily fluids

Multiple approaches to
nucleic acid isolations

Fill Out the Form or Call Us at 888.813.7253

We look forward to discussing how we can help you accelerate your biomarker discovery program

* These fields are required.